menu
    • menu

    Company profile for Bloomage Biotechnology Corp., Ltd

    NEW Drugs in Dev: 5
    Bloomage-PSE
    News
    Bloomage Showcases at China–Korea Business Forum Biomanufacturing

    09 Jan 2026

    // PRESS RELEASE

    Bloomage to Showcase Breakthrough Innovation at in-cosmetics Asia

    29 Oct 2025

    // PRESS RELEASE

    Bloomage & Xcell Therapeutics Form Strategic Partnership

    29 Sep 2025

    // PRESS RELESE

    DATA COMPILATION
    #PharmaFlow

    Bloomage Biotechnology

    Contact Supplier

    Website

    AMWC Asia-TDAC

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.pharmacompass.com/video-pharmareel/bloomage-biotechnology-corp-ltd/innovative-solution-provider

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Related CompaniesRelated Companies

    About

    Bloomage Biotechnology Corporation Limited is a global leader in bioactive materials, including mucopolysaccharides, proteins, peptides, amino acids, and natural compounds. It was the first in China to develop fermentation-based sodium hyaluronate in the 1990s. With around 200 hyaluronic acid specifications, Bloomage serves pharmaceutical, medical device, cosmetic, and functional food sectors, offering innovative solutions in aesthetics, dermatology, ophthalmology, orthopedics, and regenerative medicine. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bloomage Biotechnology Corp., LtdChina Flag
    Country
    Country
    China
    Address
    Address
    No. 678 Tianchen St.High -Tech Development Zone Jinan, Postcode 250101
    Telephone
    Telephone
    +86 53182685996
    Client Email
    Email
    wangjingbo@bloomagebiotech.com
    Client Website
    Website
    http://www.bloomagebioactive.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bloomage-biotech/
    youtube
    YouTube
    https://www.youtube.com/@bloomagebiotech8377/videos
    Twitter
    Twitter
    https://x.com/bloomagebiotech
    Contact Info
    Others

    US Subsidiary
    Address: 4 Commerce Rd. Fairfield NJ 07004
    Tel: +1 973 428 4925

    European Subsidiary
    Address: 5 Place De La Pyramide Tour Ariane La Defense, 92088, Paris, France
    Tel: +3 3659244750

    Korea Subsidiary
    Address: Unit 1912, 19th floor, Building E,11 Dangsan-ro 41-gil, Yeongdeungpo-gu, Seoul, South Korea

    Japan Subsidiary
    Address: 3−19, 4F-A Shimizu Bld. Hayabusacho, Chiyoda-ku, Tokyo 102-0092, Japan
    Tel: 81-3-6256-9688

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    VLOG #PharmaReel

    read-more

    ReelPharmaInnovative Solution ProviderInnovative Solution Provider

    Innovative Solution Provider
    Innovative Solution Provider

    reelInnovative Solution Provider

    This PharmaReel highlights Bloomage Biotechnology as an innovative solutions provider in bioactive materials, specializing in Sodium Hyaluronate and Hyaluronic Acid. The company is backed by active USDMFs, CEP, JDMF, and KDMF filings, offers over 200 product specifications, operates FDA-inspected, GMP-certified manufacturing facilities, and supplies customers across more than 70 countries.

    Impressions: 1302

    read-more

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/bloomage-biotechnology-corp-ltd-party-content-28152.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Bloomstem Cell Culture Medium - Product List

    read-more

      https://www.pharmacompass.com/pdf/party/content/bloomage-biotechnology-corp-ltd-party-content-80433.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    BloomStem™ MSC Cell Culture Medium

    read-more

      https://www.pharmacompass.com/pdf/party/content/bloomage-biotechnology-corp-ltd-party-content-82384.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    BloomseaN™ Polynucleotide (PN)

    read-more

      https://www.pharmacompass.com/pdf/party/content/bloomage-biotechnology-corp-ltd-party-content-95970.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    BloomseaN Polydeoxyribonucleotide (PDRN)

    read-more

      https://www.pharmacompass.com/pdf/party/content/bloomage-biotechnology-corp-ltd-party-content-94185.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Bloomecto Ectoine

    read-more

      https://www.pharmacompass.com/pdf/party/content/bloomage-biotechnology-corp-ltd-party-content-17290.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Bloomcolla™ Recombinant Human Collagen III

    read-more

      https://www.pharmacompass.com/pdf/party/content/bloomage-biotechnology-corp-ltd-party-content-8421.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Hyatrue® Sodium Hyaluronate

    read-more

      https://www.pharmacompass.com/pdf/party/content/bloomage-biotechnology-corp-ltd-party-content-93638.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications:     Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities:     Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program:     Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4200

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions

    #PharmaFlow by PHARMACOMPASS
    13 Nov 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Bloomage Showcases at China–Korea Business Forum Biomanufacturing
    Bloomage Showcases at China–Korea Business Forum Biomanufacturing

    09 Jan 2026

    // PRESS RELEASE

    https://www.bloomagebioactive.com/En/News/Info/16757

    PRESS RELEASE
    09 Jan 2026
    Share Share
    Bloomage to Showcase Breakthrough Innovation at in-cosmetics Asia
    Bloomage to Showcase Breakthrough Innovation at in-cosmetics Asia

    29 Oct 2025

    // PRESS RELEASE

    http://www.bloomagebioactive.com/En/News/Info/16358

    PRESS RELEASE
    29 Oct 2025
    Share Share
    Bloomage & Xcell Therapeutics Form Strategic Partnership
    Bloomage & Xcell Therapeutics Form Strategic Partnership

    29 Sep 2025

    // PRESS RELESE

    http://www.bloomagebioactive.com/En/News/Info/16250

    PRESS RELESE
    29 Sep 2025
    Share Share
    Bloomage and LG Household & Health Care Sign Memorandum
    Bloomage and LG Household & Health Care Sign Memorandum

    24 Sep 2025

    // PRESS RELEASE

    http://www.bloomagebioactive.com/En/News/Info/16201

    PRESS RELEASE
    24 Sep 2025
    Share Share
    Focusing on IFSCC: Bloomage Takes the Stage at the 35th IFSCC
    Focusing on IFSCC: Bloomage Takes the Stage at the 35th IFSCC

    22 Sep 2025

    // PRESS RELEASE

    http://www.bloomagebioactive.com/En/News/Info/16188

    PRESS RELEASE
    22 Sep 2025
    Share Share
    Bloomage Achieves FDA GMP Audit with Zero-Deficiency
    Bloomage Achieves FDA GMP Audit with Zero-Deficiency

    22 Jul 2025

    // PRESS RELEASE

    https://www.bloomagebioactive.com/En/News/Info/15662

    PRESS RELEASE
    22 Jul 2025
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company
    Bloomage Biotechnology

    Others

    read-more
    read-more

    ABOUT THIS PAGE

    Contact Bloomage Biotechnology Corp., Ltd and get a quotation

    Bloomage Biotechnology Corp., Ltd is a supplier offers 7 products (APIs, Excipients or Intermediates).

    Find Sodium Hyaluronate bulk with DMF, CEP, JDMF offered by Bloomage Biotechnology Corp., Ltd

    Find Sodium Hyaluronate bulk with DMF, CEP offered by Bloomage Biotechnology Corp., Ltd

    Find Ectoine bulk with DMF offered by Bloomage Biotechnology Corp., Ltd

    Find Collagen Peptide bulk offered by Bloomage Biotechnology Corp., Ltd

    Find Hyaluronic Acid bulk offered by Bloomage Biotechnology Corp., Ltd

    Find Sodium DNA bulk offered by Bloomage Biotechnology Corp., Ltd

    Find Sodium Hyaluronate bulk offered by Bloomage Biotechnology Corp., Ltd

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search